Trialogics is a Highly Experienced and Dedicated Team of eClinical Professionals
As CEO and Founder of Trialogics, Chris brings a wealth of technical expertise and clinical knowledge to the team. He understands that technology is a tool to help find a cure and different trials require different technology to succeed. He founded Trialogics to solve the problem of outdated, inflexible eClinical software. He guided the development team in developing software that is customized to meet specific clinical trial needs.
John Moore has been Executive Chairman of Trialogics since inception. He has invested in energy, new materials, medical devices and biotech. In 2002, he co-founded Edson Moore Healthcare Ventures to acquire sixteen interests in biotech companies from Elan Pharmaceuticals for $148 million. He served as Chairman of ImaRx Therapeutics and Elite Pharmaceuticals as well as holding numerous other biotech company board positions. He believes the best new business idea is to solve the biggest headache of his last business. He is excited by Trialogics mission to help deliver faster cures through better systems. He founded Trialogics to solve the problem of outdated, inflexible eClinical software. He guided the development team in developing software that is customized to meet specific clinical trial needs.
Edoardo co-founded Top Quartile Partners (‘TQP’) in 2007. TQP’s focus is on direct investments. Edoardo’s portfolio includes investments in communication software, healthcare, luxury goods, funeral services and Saas. In 2012 he completed the buy-out of Groupe Roc Eclerc (a leading French funeral services company) together with French entrepreneur Daniel Abittan. Most recently, Edoardo completed an investment in Useed, a leader in providing crowd-funding solutions to higher education institutions and Trialogics.
Our team has experience in multiple industries including financial, energy, and new media.
We have utilized our experience from multiple disciplines to deliver the best systems to our clients.
This diversity, coupled with clinical software development, provides a technically sound and secure experience leading to better results for our clients.
We have a proven ability to execute and an understanding of business imperatives that drive successful management and performance of global clinical trials.